MXPA03001837A - Inhibidores de adhesion celular alfa4-mediada. - Google Patents

Inhibidores de adhesion celular alfa4-mediada.

Info

Publication number: MXPA03001837A
Authority: MX; Mexico
Prior art keywords: inhibitors; cell adhesion; mediated cell; sup; alpha4
Prior art date: 2000-08-31

Application number

MXPA03001837A

Other languages

English (en)

Inventor

Ila Sircar

Original Assignee

Tanabe Seiyaku Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-31

Filing date

2001-08-27

Publication date

2003-10-15

2001-08-27 Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co

2003-10-15 Publication of MXPA03001837A publication Critical patent/MXPA03001837A/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Virology (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Obesity (AREA)
Endocrinology (AREA)
AIDS & HIV (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)

MXPA03001837A 2000-08-31 2001-08-27 Inhibidores de adhesion celular alfa4-mediada. MXPA03001837A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22912800P	2000-08-31	2000-08-31
PCT/US2001/026594 WO2002018320A2 (en)	2000-08-31	2001-08-27	INHIBITORS OF α4 MEDIATED CELL ADHESION

Publications (1)

Publication Number	Publication Date
MXPA03001837A true MXPA03001837A (es)	2003-10-15

Family

ID=22859926

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MXPA03001837A MXPA03001837A (es)	2000-08-31	2001-08-27	Inhibidores de adhesion celular alfa4-mediada.

Country Status (28)

Country	Link
US (6)	US7026501B2 (es)
EP (1)	EP1315694B1 (es)
JP (1)	JP3899022B2 (es)
KR (1)	KR100528049B1 (es)
CN (1)	CN1229334C (es)
AR (1)	AR034556A1 (es)
AT (1)	ATE292615T1 (es)
AU (2)	AU8677801A (es)
BR (1)	BR0113629A (es)
CA (1)	CA2418054C (es)
CZ (1)	CZ303460B6 (es)
DE (1)	DE60109943T2 (es)
DK (1)	DK1315694T3 (es)
ES (1)	ES2240509T3 (es)
HK (1)	HK1052684B (es)
HU (1)	HUP0302693A3 (es)
IL (2)	IL154305A0 (es)
MX (1)	MXPA03001837A (es)
MY (1)	MY129000A (es)
NO (1)	NO327861B1 (es)
NZ (1)	NZ524043A (es)
PL (1)	PL206656B1 (es)
PT (1)	PT1315694E (es)
RU (1)	RU2250895C2 (es)
SI (1)	SI1315694T1 (es)
TW (1)	TWI224587B (es)
WO (1)	WO2002018320A2 (es)
ZA (1)	ZA200301039B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU228914B1 (hu)	2000-08-18	2013-06-28	Ajinomoto Kk	Fenilalanin-származékok
TWI312347B (en)	2001-02-08	2009-07-21	Eisai R&D Man Co Ltd	Bicyclic nitrogen-containing condensed ring compounds
CA2443802C (en)	2001-04-27	2010-04-13	Eisai Co., Ltd.	Pyrazolo[1,5-a]pyridines and medicines containing the same
MY140707A (en) *	2002-02-28	2010-01-15	Mitsubishi Tanabe Pharma Corp	Process for preparing a phenylalanine derivative and intermediates thereof
CA2493008A1 (en)	2002-08-09	2004-02-19	Transtech Pharma, Inc.	Aryl and heteroaryl compounds and methods to modulate coagulation
AU2003275589B2 (en) *	2002-10-22	2009-05-28	Eisai R & D Management Co., Ltd.	7-phenyl pyrazolopyridine compounds
US7176216B2 (en)	2002-10-22	2007-02-13	Eisai Co., Ltd.	7-phenylpyrazolopyridine compounds
US7208601B2 (en)	2003-08-08	2007-04-24	Mjalli Adnan M M	Aryl and heteroaryl compounds, compositions, and methods of use
US7501538B2 (en)	2003-08-08	2009-03-10	Transtech Pharma, Inc.	Aryl and heteroaryl compounds, compositions and methods of use
AU2004263508A1 (en) *	2003-08-08	2005-02-17	Transtech Pharma, Inc.	Aryl and heteroaryl compounds, compositions, and methods of use
AU2004303696B2 (en)	2003-12-22	2011-03-31	Ea Pharma Co., Ltd.	Novel phenylalanine derivative
US7410971B2 (en)	2003-12-26	2008-08-12	Eisai R&D Management Co., Ltd.	1,2-di(cyclic)substituted benzene compounds
MY140489A (en)	2003-12-26	2009-12-31	Eisai R&D Man Co Ltd	1,2-di (cyclic) substituted benzene compounds
US7419666B1 (en)	2004-02-23	2008-09-02	Massachusetts Eye And Ear Infirmary	Treatment of ocular disorders
CA2591757C (en)	2004-12-20	2014-03-25	Makoto Kotake	Crystal and salt of 1-cyclopropylmethyl-4-[2-(3,3,5,5)-tetramethylcyclohexyl)phenyl]piperazine
CA2610800A1 (en)	2005-06-09	2006-12-14	Ucb Pharma, S.A.	2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
US20090137601A1 (en) *	2005-11-23	2009-05-28	Astrazeneca Ab	L-Phenylalanine Derivatives
US7897763B2 (en)	2005-12-29	2011-03-01	Lexicon Pharmaceuticals, Inc.	Process for the preparation of substituted phenylalanines
EP1984344B1 (en) *	2005-12-29	2012-09-26	Lexicon Pharmaceuticals, Inc.	Multicyclic amino acid derivatives and methods of their use
IL172896A0 (en) *	2005-12-29	2006-06-11	Yeda Res & Dev	Cxcr4 inhibition
US7855291B2 (en)	2005-12-29	2010-12-21	Lexicon Pharmaceuticals, Inc.	Process for the preparation of substituted phenylalanines
US8808698B2 (en) *	2006-02-03	2014-08-19	The Regents Of The University Of California	Methods for inhibition of lymphangiogenesis and tumor metastasis
EP1984330A1 (en) *	2006-02-09	2008-10-29	AstraZeneca AB	Chemical compounds
EP2007392A4 (en) *	2006-02-28	2010-04-07	Elan Pharm Inc	METHOD FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4-INHIBITABLE COMPOUNDS
WO2007100770A2 (en) *	2006-02-28	2007-09-07	Elan Pharmaceuticals, Inc.	Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2007103112A2 (en)	2006-03-03	2007-09-13	Elan Pharmaceuticals, Inc.	Methods of treating inflammatory and autoimmune diseases with natalizumab
CN101801384B (zh) *	2007-08-24	2012-03-21	莱西肯医药有限公司	制备基于4-苯基-6-(2，2，2-三氟-1-苯基乙氧基)嘧啶的化合物的方法
RS52561B (en)	2008-04-15	2013-04-30	Eisai R&D Management Co., Ltd.	COMPOUND 3-PHENYLPYRAZOLO [5,1-B] THIAZOL
AR078521A1 (es)	2009-10-08	2011-11-16	Eisai R&D Man Co Ltd	Compuesto pirazolotiazol
MX2012004707A (es) *	2009-10-21	2012-06-08	Glaxo Group Ltd	Proceso para la preparacion de un derivado de fenilalanina.
US11287423B2 (en)	2010-01-11	2022-03-29	Biogen Ma Inc.	Assay for JC virus antibodies
SMT202200445T1 (it)	2010-01-11	2023-01-13	Biogen Ma Inc	Saggio per anticorpi del virus jc
CN103635803A (zh)	2011-05-31	2014-03-12	比奥根艾迪克Ma公司	评估进行性多灶性白质脑病风险的方法
US20150010563A1 (en) *	2012-02-21	2015-01-08	Massachusetts Eye & Ear Infirmary	Methods for Treating Corneal and Conjunctival Inflammation and Inflammatory Disorders
HK1216546A1 (zh)	2013-05-28	2016-11-18	Biogen Ma Inc.	評估pml風險的方法
WO2018085552A1 (en) *	2016-11-02	2018-05-11	Saint Louis University	Integrin antagonists
CA3114240C (en)	2018-10-30	2023-09-05	Gilead Sciences, Inc.	Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
EP3873884B1 (en)	2018-10-30	2024-12-04	Gilead Sciences, Inc.	3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dione derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
CN112969504B (zh)	2018-10-30	2024-04-09	吉利德科学公司	用于抑制α4β7整合素的化合物
CA3115820A1 (en)	2018-10-30	2020-05-07	Gilead Sciences, Inc.	Compounds for inhibition of .alpha.4.beta.7 integrin
US11578069B2 (en)	2019-08-14	2023-02-14	Gilead Sciences, Inc.	Compounds for inhibition of α4 β7 integrin

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK148576A (da)	1975-04-18	1976-10-19	Boehringer Mannheim Gmbh	Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling
RU2126418C1 (ru)	1993-11-01	1999-02-20	Циба-Гейги Джапан Димитед	Антагонисты рецепторов эндотелина
EP0753004A1 (en)	1994-03-28	1997-01-15	Japat Ltd	Antagonists of endothelin receptors
US6306840B1 (en)	1995-01-23	2001-10-23	Biogen, Inc.	Cell adhesion inhibitors
AU5687396A (en)	1995-04-21	1996-11-07	Novarits Ag	N-aroylamino acid amides as endothelin inhibitors
JP2002512625A (ja)	1997-05-29	2002-04-23	メルクエンドカンパニーインコーポレーテッド	細胞接着阻害薬としての複素環アミド化合物
JP2002501537A (ja)	1997-05-29	2002-01-15	メルクエンドカンパニーインコーポレーテッド	細胞接着阻害薬としてのスルホンアミド類
JP2001517245A (ja)	1997-05-29	2001-10-02	メルクエンドカンパニーインコーポレーテッド	細胞接着阻害薬としてのビアリールアルカン酸類
EP0984981B1 (en)	1997-05-30	2003-12-17	Celltech Therapeutics Limited	Anti-inflammatory tyrosine derivatives
DE69818049T2 (de)	1997-06-23	2004-07-15	Tanabe Seiyaku Co., Ltd.	Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
IL133637A0 (en)	1997-07-31	2001-04-30	Elan Pharm Inc	Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
KR20010022414A (ko)	1997-07-31	2001-03-15	진 엠. 듀발	Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제시키는4-아미노-페닐알라닌형 화합물
AR016133A1 (es)	1997-07-31	2001-06-20	Wyeth Corp	Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
HUP0004529A3 (en)	1997-07-31	2001-05-28	American Home Prod	Sulfonilated dipeptide-compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
EP1001975A1 (en)	1997-07-31	2000-05-24	Elan Pharmaceuticals, Inc.	Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
JP2001512135A (ja)	1997-07-31	2001-08-21	エラン・ファーマシューティカルズ・インコーポレーテッド	Ｖｌａ−４によって媒介された白血球接着を阻害するジペプチドおよび関連化合物
KR20010022411A (ko)	1997-07-31	2001-03-15	진 엠. 듀발	Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제하는 치환된페닐알라닌계의 화합물
IL133642A0 (en)	1997-07-31	2001-04-30	Elan Pharm Inc	Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
PT1005445E (pt)	1997-08-22	2004-09-30	Hoffmann La Roche	Derivados de n-alcanoilfenilalanina
ATE260243T1 (de)	1997-08-22	2004-03-15	Hoffmann La Roche	N-aroylphenylalaninderivate
US6191171B1 (en)	1997-11-20	2001-02-20	Merck & Co., Inc.	Para-aminomethylaryl carboxamide derivatives
WO1999026922A1 (en)	1997-11-21	1999-06-03	Merck & Co., Inc.	Substituted pyrrole derivatives as cell adhesion inhibitors
AU750175B2 (en)	1997-11-24	2002-07-11	Merck & Co., Inc.	Cyclic amino acid derivatives as cell adhesion inhibitors
ATE267168T1 (de)	1997-11-24	2004-06-15	Merck & Co Inc	Beta-alanin-derivate als zell-adhäsions- inhibitoren
US6197794B1 (en)	1998-01-08	2001-03-06	Celltech Therapeutics Limited	Phenylalanine derivatives
MY153569A (en) *	1998-01-20	2015-02-27	Mitsubishi Tanabe Pharma Corp	Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en)	1998-01-27	2001-12-11	Celltech Therapeutics Limited	Phenylalanine derivatives
WO1999043642A1 (en)	1998-02-26	1999-09-02	Celltech Therapeutics Limited	Phenylalanine derivatives as inhibitors of alpha4 integrins
US6521626B1 (en)	1998-03-24	2003-02-18	Celltech R&D Limited	Thiocarboxamide derivatives
GB9811159D0 (en)	1998-05-22	1998-07-22	Celltech Therapeutics Ltd	Chemical compounds
GB9812088D0 (en)	1998-06-05	1998-08-05	Celltech Therapeutics Ltd	Chemical compounds
WO1999064395A1 (en)	1998-06-11	1999-12-16	Merck & Co., Inc.	Heterocyclic amide compounds as cell adhesion inhibitors
TW591026B (en)	1998-06-23	2004-06-11	Upjohn Co	Inhibitors of alpha4beta1 mediated cell adhesion
PT1144365E (pt)	1998-12-22	2004-06-30	Tanabe Seiyaku Co	Inibidores da adesao de celulas mediada por alfa4beta1
GB2354440A (en)	1999-07-20	2001-03-28	Merck & Co Inc	Aryl amides as cell adhesion inhibitors
US6420418B1 (en)	1999-08-16	2002-07-16	Merck & Co., Inc.	Heterocycle amides as cell adhesion inhibitors
AU6909300A (en)	1999-08-20	2001-03-19	Merck & Co., Inc.	Substituted ureas as cell adhesion inhibitors
JP2003509488A (ja)	1999-09-24	2003-03-11	ジェネンテック・インコーポレーテッド	チロシン誘導体
WO2002018329A1 (en)	2000-08-31	2002-03-07	Eli Lilly And Company	Acetylenic sulfonamide derivatives

2001
- 2001-08-21 MY MYPI20013917A patent/MY129000A/en unknown
- 2001-08-27 BR BR0113629-1A patent/BR0113629A/pt active Search and Examination
- 2001-08-27 KR KR10-2003-7001993A patent/KR100528049B1/ko not_active Expired - Fee Related
- 2001-08-27 CZ CZ20030487A patent/CZ303460B6/cs not_active IP Right Cessation
- 2001-08-27 HU HU0302693A patent/HUP0302693A3/hu unknown
- 2001-08-27 WO PCT/US2001/026594 patent/WO2002018320A2/en active IP Right Grant
- 2001-08-27 EP EP01966246A patent/EP1315694B1/en not_active Expired - Lifetime
- 2001-08-27 SI SI200130351T patent/SI1315694T1/xx unknown
- 2001-08-27 CA CA 2418054 patent/CA2418054C/en not_active Expired - Fee Related
- 2001-08-27 AU AU8677801A patent/AU8677801A/xx active Pending
- 2001-08-27 ZA ZA200301039A patent/ZA200301039B/xx unknown
- 2001-08-27 IL IL15430501A patent/IL154305A0/xx unknown
- 2001-08-27 NZ NZ524043A patent/NZ524043A/en not_active IP Right Cessation
- 2001-08-27 AU AU2001286778A patent/AU2001286778B2/en not_active Ceased
- 2001-08-27 JP JP2002523438A patent/JP3899022B2/ja not_active Expired - Fee Related
- 2001-08-27 DK DK01966246T patent/DK1315694T3/da active
- 2001-08-27 HK HK03105043.3A patent/HK1052684B/en not_active IP Right Cessation
- 2001-08-27 AT AT01966246T patent/ATE292615T1/de active
- 2001-08-27 PL PL365668A patent/PL206656B1/pl unknown
- 2001-08-27 CN CNB018149871A patent/CN1229334C/zh not_active Expired - Fee Related
- 2001-08-27 RU RU2003105885/04A patent/RU2250895C2/ru not_active IP Right Cessation
- 2001-08-27 PT PT01966246T patent/PT1315694E/pt unknown
- 2001-08-27 US US10/333,985 patent/US7026501B2/en not_active Expired - Fee Related
- 2001-08-27 DE DE60109943T patent/DE60109943T2/de not_active Expired - Lifetime
- 2001-08-27 MX MXPA03001837A patent/MXPA03001837A/es active IP Right Grant
- 2001-08-27 ES ES01966246T patent/ES2240509T3/es not_active Expired - Lifetime
- 2001-08-31 TW TW090121581A patent/TWI224587B/zh not_active IP Right Cessation
- 2001-08-31 AR ARP010104172A patent/AR034556A1/es active IP Right Grant
2003
- 2003-02-05 IL IL154305A patent/IL154305A/en not_active IP Right Cessation
- 2003-02-25 NO NO20030885A patent/NO327861B1/no not_active IP Right Cessation
2005
- 2005-07-13 US US11/179,729 patent/US7456217B2/en not_active Expired - Fee Related
2008
- 2008-10-07 US US12/247,129 patent/US7671090B2/en not_active Expired - Fee Related
2010
- 2010-01-07 US US12/683,648 patent/US7872151B2/en not_active Expired - Fee Related
- 2010-12-08 US US12/962,707 patent/US8501809B2/en not_active Expired - Fee Related
2013
- 2013-07-03 US US13/934,405 patent/US20130289109A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20030176498A1 (en)	2003-09-18
EP1315694B1 (en)	2005-04-06
KR100528049B1 (ko)	2005-11-15
WO2002018320A2 (en)	2002-03-07
HUP0302693A3 (en)	2005-05-30
US20130289109A1 (en)	2013-10-31
KR20030059099A (ko)	2003-07-07
AU2001286778B2 (en)	2005-02-10
US20090111879A1 (en)	2009-04-30
CZ2003487A3 (cs)	2003-06-18
US7026501B2 (en)	2006-04-11
US7872151B2 (en)	2011-01-18
HK1052684B (en)	2005-07-22
DE60109943D1 (de)	2005-05-12
CZ303460B6 (cs)	2012-09-26
NO20030885L (no)	2003-02-25
ZA200301039B (en)	2004-02-09
MY129000A (en)	2007-03-30
CN1449377A (zh)	2003-10-15
PL365668A1 (en)	2005-01-10
NZ524043A (en)	2004-08-27
RU2250895C2 (ru)	2005-04-27
US20100113820A1 (en)	2010-05-06
US7456217B2 (en)	2008-11-25
TWI224587B (en)	2004-12-01
US8501809B2 (en)	2013-08-06
ATE292615T1 (de)	2005-04-15
DE60109943T2 (de)	2006-02-09
AU8677801A (en)	2002-03-13
IL154305A0 (en)	2003-09-17
SI1315694T1 (en)	2005-10-31
CA2418054C (en)	2008-08-05
WO2002018320A3 (en)	2002-06-06
JP3899022B2 (ja)	2007-03-28
BR0113629A (pt)	2003-07-22
CN1229334C (zh)	2005-11-30
AR034556A1 (es)	2004-03-03
NO20030885D0 (no)	2003-02-25
IL154305A (en)	2010-11-30
NO327861B1 (no)	2009-10-05
CA2418054A1 (en)	2002-03-07
JP2004507519A (ja)	2004-03-11
US7671090B2 (en)	2010-03-02
DK1315694T3 (da)	2005-08-08
ES2240509T3 (es)	2005-10-16
US20050282900A1 (en)	2005-12-22
PL206656B1 (pl)	2010-09-30
HUP0302693A2 (hu)	2003-12-29
EP1315694A2 (en)	2003-06-04
HK1052684A1 (en)	2003-09-26
PT1315694E (pt)	2005-07-29
US20110077299A1 (en)	2011-03-31

Publication	Publication Date	Title
MXPA03001837A (es)	2003-10-15	Inhibidores de adhesion celular alfa4-mediada.
AU3260399A (en)	1999-09-15	Phenylalanine derivatives as inhibitors of alpha4 integrins
MXPA02003977A (es)	2003-09-25	Inhibidores de adhesion de celula mediada por al°2.
DE69831868D1 (en)	2006-02-23	Antithrombosemittel
TR200100432T2 (tr)	2001-09-21	Hepatit C inhibitörü tri-peptidler
EP1019045A4 (en)	2002-07-03	ANTITHROMBOTIC AGENTS
MX9800804A (es)	1998-07-31	Derivados de pirrolidina que tienen actividad inhibitoria de la fosfolipasa a2.
AU5949294A (en)	1994-10-20	1H-indole-3-acetamide sPLA2 inhibitors
WO2001064645A3 (en)	2001-12-27	Derivatives of quinoline as alpha-2 antagonists
EP1175208A4 (en)	2003-05-21	COMPOSITION FOR PREVENTION OR TREATMENT OF DEMENTIA CONTAINING A HYDROXYCINNAMIC ACID DERIVATIVE OR AN EXTRACT OF AN ANGELICAE SPECIES CONTAINING SAID ACID
DE60114640D1 (en)	2005-12-08	Antithrombosemittel
EP1434762A4 (en)	2006-01-04	4'-METHANSULFONYLBIPHENYL DERIVATIVES AS HIGH-DETECTIVE CYCLOOXYGENASE-2 INHIBITORS
IL144126A0 (en)	2002-05-23	A method of altering the specificity of cyclooxygenase-inhibiting compounds
MY118704A (en)	2005-01-31	Process for preparation of eprosartan
AU3285000A (en)	2000-09-28	22r-hydroxycholesta-8,14-diene derivatives for the inhibition of meiosis
AP2001002314A0 (en)	2001-12-31	Substituted benzolactam compounds.
TW262467B (es)	1995-11-11
MXPA02001415A (es)	2002-08-12	Proceso para elaborar una formulacion de liberacion sostenida.
IL135842A0 (en)	2001-05-20	3-carboalkoxy -2,3-dihydro-1h-phenothiazin-4[10h]-one derivatives
RS50449B (sr)	2010-03-02	Supstituisani bisindolilmaleimidi za inhibiciju proliferacije ćelija
AP9400608A0 (en)	1995-07-12	"New nicotinic acid derivative".
SE9800932D0 (sv)	1998-03-20	New compunds
WO2002050028A3 (en)	2002-09-19	Substituted benzoindoles as spla2 inhibitors
AU1847401A (en)	2001-06-12	Diketopiperazine derivatives to inhibit thrombin

Legal Events

Date	Code	Title	Description
2006-01-23	FG	Grant or registration